Personalis Inc (PSNL)

$7.26 +0.07 (0.97%)
Market Cap 728.24M
Revenue (ttm) 69.65M
Net Income (ttm) -81.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -116.68%
Debt to Equity Ratio 0.00
Volume 1,917,700
Avg Vol 1,435,750
Day's Range N/A - N/A
Shares Out 104.63M
Stochastic %K 38%
Beta 2.02
Analysts Strong Sell
Price Target $11.43

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 752 1300
Fax: 650 752 1301
Address:
6600 Dumbarton Circle, Fremont, United States
Wax_Bean_futures
Wax_Bean_futures Mar. 21 at 8:00 PM
$PSNL I apologize if this has already been posted https://www.botn.bio/p/the-sensitivity-standard
0 · Reply
LordBrypto
LordBrypto Mar. 20 at 9:46 PM
$PSNL
0 · Reply
degeneratetrader23
degeneratetrader23 Mar. 20 at 7:46 PM
$PSNL lol. This stock got this selloff done with 8 days ago.
0 · Reply
BioTechNoir
BioTechNoir Mar. 20 at 6:39 PM
$PSNL good signs
0 · Reply
E444
E444 Mar. 20 at 1:14 PM
$PSNL oooo news day?
1 · Reply
Wax_Bean_futures
Wax_Bean_futures Mar. 19 at 7:08 PM
$PSNL Market just spiked. War over?
1 · Reply
arribaStocktrading
arribaStocktrading Mar. 19 at 3:00 PM
$PSNL Pam Bondi says we should be talking about the DOW. Sure. Fine. It's hit its low for the year today. Same for the S&P 500 and the NASDAQ too.
1 · Reply
BioTechNoir
BioTechNoir Mar. 18 at 4:50 PM
$PSNL strong like bull? 🤔
1 · Reply
RockyMontana
RockyMontana Mar. 18 at 2:38 PM
$PSNL short term looking like a bear flag.. expecting another low?
2 · Reply
E444
E444 Mar. 18 at 10:45 AM
$PSNL glad I bought everything I could in the 6$ range good luck to all except shorts
1 · Reply
Latest News on PSNL
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Mar 17, 2026, 4:00 PM EDT - 4 days ago

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Mar 12, 2026, 6:00 AM EDT - 9 days ago

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 11:37 PM EST - 22 days ago

Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 26, 2026, 4:01 PM EST - 23 days ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Feb 17, 2026, 4:01 PM EST - 4 weeks ago

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:01 PM EST - 5 weeks ago

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

Feb 10, 2026, 6:00 AM EST - 5 weeks ago

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Feb 2, 2026, 6:00 AM EST - 6 weeks ago

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2026, 4:01 PM EST - 7 weeks ago

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Jan 12, 2026, 4:00 PM EST - 2 months ago

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Jan 8, 2026, 8:00 AM EST - 2 months ago

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Dec 17, 2025, 6:00 AM EST - 3 months ago

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Dec 11, 2025, 9:00 AM EST - 3 months ago

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 4:01 PM EST - 4 months ago

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 10, 2025, 9:00 AM EST - 4 months ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:46 PM EST - 4 months ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 4 months ago

Personalis Reports Third Quarter 2025 Financial Results

Personalis to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 5 months ago

Personalis to Announce Third Quarter 2025 Financial Results

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Oct 16, 2025, 9:00 AM EDT - 5 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 15, 2025, 5:35 PM EDT - 6 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 10, 2025, 4:05 PM EDT - 6 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Sep 3, 2025, 4:05 PM EDT - 7 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 7 months ago

Personalis to Participate in Upcoming Investor Conferences

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Aug 6, 2025, 8:11 AM EDT - 8 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:49 PM EDT - 8 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Personalis Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:01 PM EDT - 8 months ago

Personalis Reports Second Quarter 2025 Financial Results

Personalis to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 8 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025, 4:00 PM EDT - 9 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 3, 2025, 4:00 PM EDT - 10 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Jun 2, 2025, 4:00 PM EDT - 10 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 22, 2025, 6:00 AM EDT - 10 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 14, 2025, 4:01 PM EDT - 11 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:41 PM EDT - 11 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

Personalis Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 11 months ago

Personalis Reports First Quarter 2025 Financial Results

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 28, 2025, 5:00 PM EDT - 11 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 11 months ago

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Apr 22, 2025, 6:00 AM EDT - 11 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Mar 3, 2025, 6:00 AM EST - 1 year ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:40 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 1 year ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 18, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 14, 2025, 10:50 AM EST - 1 year ago

Exciting Technology At Personalis, But Profitability Eludes Them

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 13, 2025, 5:00 AM EST - 1 year ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Jan 7, 2025, 4:01 PM EST - 1 year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 19, 2024, 9:00 AM EST - 1 year ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Dec 16, 2024, 8:00 AM EST - 1 year ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Wax_Bean_futures
Wax_Bean_futures Mar. 21 at 8:00 PM
$PSNL I apologize if this has already been posted https://www.botn.bio/p/the-sensitivity-standard
0 · Reply
LordBrypto
LordBrypto Mar. 20 at 9:46 PM
$PSNL
0 · Reply
degeneratetrader23
degeneratetrader23 Mar. 20 at 7:46 PM
$PSNL lol. This stock got this selloff done with 8 days ago.
0 · Reply
BioTechNoir
BioTechNoir Mar. 20 at 6:39 PM
$PSNL good signs
0 · Reply
E444
E444 Mar. 20 at 1:14 PM
$PSNL oooo news day?
1 · Reply
Wax_Bean_futures
Wax_Bean_futures Mar. 19 at 7:08 PM
$PSNL Market just spiked. War over?
1 · Reply
arribaStocktrading
arribaStocktrading Mar. 19 at 3:00 PM
$PSNL Pam Bondi says we should be talking about the DOW. Sure. Fine. It's hit its low for the year today. Same for the S&P 500 and the NASDAQ too.
1 · Reply
BioTechNoir
BioTechNoir Mar. 18 at 4:50 PM
$PSNL strong like bull? 🤔
1 · Reply
RockyMontana
RockyMontana Mar. 18 at 2:38 PM
$PSNL short term looking like a bear flag.. expecting another low?
2 · Reply
E444
E444 Mar. 18 at 10:45 AM
$PSNL glad I bought everything I could in the 6$ range good luck to all except shorts
1 · Reply
BioTechNoir
BioTechNoir Mar. 18 at 1:55 AM
$PSNL RC please bring us to the promised land in your expanded role!!
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 17 at 9:05 PM
$PSNL Share Price: $7.12 Contract Selected: Oct 16, 2026 $7.5 Calls Buy Zone: $0.34 – $0.42 Target Zone: $0.54 – $0.66 Potential Upside: 50% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Wax_Bean_futures
Wax_Bean_futures Mar. 17 at 8:04 PM
$PSNL https://www.businesswire.com/news/home/20260317575420/en/Personalis-Appoints-Dr.-Richard-Chen-as-President-to-Further-Accelerate-MRD-Adoption
1 · Reply
Wax_Bean_futures
Wax_Bean_futures Mar. 17 at 8:01 PM
$PSNL
0 · Reply
ExNoose
ExNoose Mar. 17 at 3:24 PM
$PSNL The fundamentals haven't even kicked in yet! The data licensing angle is unpriced optionality sitting on top of an already compelling reimbursement story. Medicare coverage: breast ✅ lung ✅ IO pending. Neoadjuvant breast dossier clock started this week after a landmark JCO publication , 227 patients, 24 cancer centres showing NeXT Personal outperformed every standard clinical metric including pathological complete response. 43,000–45,000 tests guided for 2026. That's 170% volume growth. The longitudinal dataset compounds every single year. $240M cash. No forced dilution. Management that raised $109M at the highs. The AI data story is what nobody is modelling yet~~
1 · Reply
ExNoose
ExNoose Mar. 17 at 3:22 PM
$PSNL https://lefkofsky.com/see-spot-run/ Tempus CEO just wrote the bull case without mentioning it! Lefkofsky's latest piece explains why big tech is now calling Tempus asking one question: "How much of your data has longitudinal patient journeys with outcome and response?" He calls it "the holy grail" for AI prediction models. Static tissue genomics is a snapshot. What Personalis generates is a movie — the same patient tracked across years of blood draws, ctDNA rising and falling months before any scan sees anything. 55% of detections occur below 100ppm. Invisible to every competitor on the market. Tempus built ~$2B in licensing deals on tissue snapshots. The next wave of AI demand is longitudinal molecular prediction. That data lives inside the Tempus-Personalis partnership exclusive through 2029. Lefkofsky described the holy grail. Personalis is generating it.
0 · Reply
arribaStocktrading
arribaStocktrading Mar. 17 at 12:38 PM
$PSNL I've been reading all about the war and I suppose y'all have too. Let me share a few things that I've learned. Supposedly, the US ran through about a year's worth of munitions in just the 1st 2 weeks of the war. Tungsten is essential for the manufacture of these munitions and the US mines none -ZERO-of its own tungsten. The US had been importing Tungsten mostly from China which has 85 percent of the world's Tungsten and has now placed import controls which could deny the US a valuable component of their munitions arsenal going forward. There are alternative suppliers but they are much more expensive and not-well established and output is low for now. 20 percent of the world's oil and 30 percent of the world's fertilizer flows through the Strait of Hormuz. Qatar supplies 30 percent of the world's helium and they have completely shut down production. Without helium, you cannot make Semiconductors. It's also used in many things like MRI scans. Unintended consequences....
2 · Reply
magnitudeFC
magnitudeFC Mar. 16 at 3:46 PM
$PSNL Interview with PSNL CEO Chris Hall. He doesn't say anything that we didn't already know, but good to hear from him regardless. Note that this interview is from earlier this year at the JP Morgan conference: https://t.co/LI3MewvxMf
0 · Reply
ExNoose
ExNoose Mar. 16 at 1:12 PM
$PSNL https://www.youtube.com/watch?v=jAL4KT1cWus Tempus CEO Eric Lefkofsky on big tech interest in genomics data: "A year ago I couldn't get any big tech company to even engage. Now we're in conversations with half of them and my guess is a year from now all of them." Tempus has 450 petabytes of data, approaching 10 million cancer patients. Hospitals that once refused to share data are now asking "how do I make money off this?" Tempus's MRD data runs exclusively on Personalis technology, 4,700 tests last quarter and 45,000 projected for 2026, across a partnership extended to 2029. Lefkofsky described what makes data most valuable to AI: longitudinal patient histories. The same patient tracked across years of blood draws, ctDNA rising and falling months before imaging sees anything. That data comes from Personalis. Precision oncology per Lefkofsky: "We're a six or seven heading to a nine or ten. It'll happen." The reimbursement story is the headline. The data story is the one nobody is modelling yet!
1 · Reply
arribaStocktrading
arribaStocktrading Mar. 16 at 1:56 AM
$PSNL Futures were up but then Trump starts running his mouth again like always. It's going to be a fun week ahead. Yeah baby.
1 · Reply
BioTechNoir
BioTechNoir Mar. 13 at 2:52 PM
$PSNL 😎
0 · Reply
magnitudeFC
magnitudeFC Mar. 13 at 2:22 PM
$PSNL guys I think I have a problem. I can't stop buying $PSNL. I may need an intervention soon.
2 · Reply